Allscripts Healthcare Solutions

Veradigm, Inc. engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units. The firm solutions include All EMRs, All Population Health Management, Patient Engagement, and Precision Medicine. The company was founded in 1986 and is headquartered in Chicago, IL.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Veradigm, a business unit of Allscripts (NASDAQ: MDRX), announced today that Veradigm EHR (formerly known as Professional EHR) has achieved 2015 ONC Health IT Update Certification.

Veradigm EHR Achieves 2015 ONC Health IT Update Certification

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Jenny Gelinas - VP, IR Richard Poulton - CEO Thomas Langan - President and Chief Commercial Officer Leah Jones - CFO Conference Call Participants Stephanie Davis - SVB Securities Charles Rhyee - Cowen and Company Thomas Keller - RBC Capital Markets George Hill - Deutsche Bank Cynthia Motz - Goldman Sachs Eric Percher - Nephron Research Operator Greetings, and welcome to Allscripts' Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Allscripts Healthcare Solutions, Inc. (MDRX) Q3 2022 Earnings Call Transcript

Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.

Allscripts (MDRX) Q3 Earnings Surpass Estimates, Margins Up

AllScripts (MDRX) delivered earnings and revenue surprises of 21.05% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AllScripts Healthcare (MDRX) Q3 Earnings Top Estimates

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three and nine months ended September 30, 2022.

Allscripts announces third quarter of 2022 results

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Allscripts Healthcare Solutions, Inc. (Nasdaq:MDRX) will report its financial results for the three months ended September 30, 2022 after the close of stock market hours on Thursday, November 3, 2022.

Allscripts to release third-quarter 2022 financial results November 3

Omnicell

MDRX vs. OMCL: Which Stock Is the Better Value Option?

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) will host a virtual Investor Day on Wednesday, September 28, 2022 at 12:00 p.m. (Eastern). The event will include presentations made by members of the executive management team followed by a question-and-answer session. Participants may access the virtual conference by registering with our webcast registration or dial-in registration (for Q&A) links. Presentation slides will be posted on the day of the event, at

Allscripts to Host Virtual Investor Day September 28th

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), and Vytalize Health, a new kind of Medicare ACO focused on helping primary care doctors manage their Medicare patients, announced today a new agreement for Vytalize Health to integrate its solutions and services directly into the Practice Fusion EHR, a Veradigm Network solution. Value-based care is rapidly becoming the standar

Veradigm and Vytalize Health: Paving the Way for Primary Care Physicians to Improve Patient Outcomes

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

Here's Why You Should Hold on to Allscripts (MDRX) Stock Now

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), today announced that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Payerpath™ first for 2022 in its End-To-End RCM Software Technology, Physicians Practices & Ambulatory Facilities/Groups Solutions category. Veradigm Payerpath is an end-to-end reven

Veradigm Payerpath Ranks First in End-To-End Revenue Cycle Management (RCM) Software Technology from Black Book™ Research

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), today announced that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Payerpath™ #1 for 2022 in its Ambulatory Claims Management and Clearinghouse Solutions category. Veradigm Payerpath is an end-to-end revenue cycle management suite of solutions built to

Veradigm Payerpath Ranked as #1 Solution for 2022 by Black Book

MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?

The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in AllScripts (MDRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can AllScripts (MDRX) Climb 27% to Reach the Level Wall Street Analysts Expect?

Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.

Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jenny Gelinas - VP, IR Rick Poulton - CEO Tom Langan - President and Chief Commercial Officer Leah Jones - CFO Conference Call Participants Stephanie Davis - SVB Securities Cindy Motz - Goldman Sachs Charles Rhyee - Cowen Sean Dodge - RBC Capital Michael Cherny - Bank of America George Hill - Deutsche Bank Jeff Garro - Piper Stanley Dolph Warburton - Nephron Research Operator Ladies and gentlemen, good day, and thank you for joining us for this Allscripts Q2 2022 Earnings Conference Call. [Operator Instructions] Also a friendly reminder, today's session is being recorded.

Allscripts Healthcare Solutions, Inc. (MDRX) CEO Rick Poulton on Q2 2022 Results - Earnings Call Transcript

AllScripts (MDRX) delivered earnings and revenue surprises of 12.50% and 2.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AllScripts Healthcare (MDRX) Tops Q2 Earnings and Revenue Estimates

CHICAGO--(BUSINESS WIRE)---- $MDRX #healthIT--Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three and six months ended June 30, 2022. Second quarter 2022 Veradigm revenue was $145 million compared with $133 million in the second quarter of 2021. On a consolidated Allscripts basis second quarter 2022 revenue was $151 million compared with $141 million in the second quarter of 2021. In the second quarter, Allscripts completed the sale of its Hospital and La

Allscripts Announces Second Quarter of 2022 Results

Earnings Preview: AllScripts Healthcare (MDRX) Q2 Earnings Expected to Decline

CHICAGO--(BUSINESS WIRE)--Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) will report its financial results for the three months ended June 30, 2022 after the close of stock market hours on Thursday, August 4, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Second-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close o

Allscripts to Release Second-Quarter 2022 Financial Results August 4

CHICAGO--(BUSINESS WIRE)--Pulse8 is thrilled to announce that Qualit8, a Veradigm Network Solution, has achieved MY2022 Measure Certification from the National Committee for Quality Assurance (NCQA) for the third consecutive year. Veradigm® is a leading provider of healthcare data, analytics and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX). By earning NCQA Measure Certification, the industry's most rigorous assessment, Qualit8 demonstrates a commitm

Pulse8 Receives NCQA Measure Certification™ for HEDIS® MY2022 for Qualit8™, a Veradigm Network Solution

CHICAGO--(BUSINESS WIRE)--Veradigm, a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), today announced that its method and apparatus for risk adjustment patent (“Dynamic Intervention Planning”) has been issued by the United States Patent and Trademark Office (USPTO). The patent covers the systems that power Veradigm's Dynamic Intervention Planning process. These systems enable Veradigm's clients to find, size, monetize, prioritize, and resolve opportunities across different line

Veradigm Issued Patent for Risk Adjustment Method and Apparatus

Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

CHICAGO--(BUSINESS WIRE)--Researchers from Veradigm®, a leading provider of healthcare data and technology solutions, will present health economics and outcomes research (HEOR) data on Covid-19, diabetes, NASH (Non-Alcoholic Steatohepatitis), and cardiovascular disease at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Washington, D.C. from May 15-18, 2022. “Accessing real-world data from across a variety of sources provides rich evidence for better decision-mak

News for Allscripts Healthcare Solutions Stock (MDRX)